Skip to main content
Porto

PMMNG logo

  • Home
  • Our Meetings
    • Monthly PMMNG Meetings
    • Steering Committee Meetings
  • Myeloma Events
    • Upcoming Events
    • Archived Myeloma Events
  • Our Members
  • Miles for Myeloma
  • Diversity & Inclusion
  • Resources
    • Myeloma Education Resources
    • Myeloma and Cancer Foundations
    • Regional Myeloma Support Groups
    • Publications and Newsletters
    • Cancer Support Networks
    • Treatments
    • Financial Assistance
    • Caregivers
  • Clinical Trials

Archived Events

  • IMF: Patient & Family Webinar - From Best of ASH 2021 to 2022 COVID-19 Guidance
  • MMRF: Patient Summit
  • CancerCare: Coping with the Stresses of Caregiving When Your Loved One Has Multiple Myeloma
  • CancerCare: COVID-19, Omicron & Delta Variants, COVID-19 Vaccines & Booster Vaccines - Revised Guidelines for People Living with Cancer and Their Loved Ones
  • Myeloma Crowd: Looking Forward in 2022 for Multiple Myeloma with Robert Orlowski
  • CancerCare: What’s New in Diagnostic Technologies for People Living with Blood Cancers
  • Special PMMNG Meeting: Using Your Patient Data to Inform Treatment Decisions - Conversations with the MMRF and Health Tree Foundation
  • MMRF: Patient Summit
  • CancerCare: Progress in the Treatment of Multiple Myeloma
  • CancerCare: Update from the 2021 American Society of Hematology (ASH) Annual Meeting

Myeloma Crowd: Studying MGUS and Smoldering Myeloma Genetics and Using Immunotherapies in High-Risk Smoldering Myeloma with Dr. Elisabet Manasanch, MD Anderson Cancer Center

Myeloma Crowd LogoWhat: Webcast transcript
When: Friday May 5, 2017
Where: Web
More Info: https://www.myelomacrowd.org/precursor-genetics-manasanch/

Tags
event
archived
myeloma crowd
transcript
mgus
smoldering myeloma
immunotherapy
genetics